Dupilumab-Induced Pancreatitis
- PMID: 37492485
- PMCID: PMC10365188
- DOI: 10.14309/crj.0000000000001106
Dupilumab-Induced Pancreatitis
Abstract
Drug-induced pancreatitis (DIP) is a rare cause of pancreatitis with an extensive and growing list of offending medications. Drawing a causative relationship between a medication and pancreatitis can be challenging, requiring a thorough workup to exclude other potential etiologies. By using scoring systems to identify DIP, we have identified another case of suspected DIP. In this study, we present a case of pancreatitis 10 days after initiation of dupilumab. An evaluation for other causes was unrevealing. As dupilumab use increases, providers should be aware of this possible adverse effect.
Keywords: adverse effects; dupilumab; pancreatitis.
© 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.
References
-
- Regeneron Pharmaceuticals, Inc. Dupixent (Dupilumab) [package insert]. U.S. Food and Drug Administration website. (https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761055s042lbl....). Accessed October 3, 2022.
-
- Castro M, Corren J, Pavord ID, et al. . Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–96. - PubMed
-
- Mederos MA, Reber HA, Girgis MD. Acute pancreatitis: A review. JAMA. 2021;325(4):382–90. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials